Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Awaiting development
Reference number: GID-TA11215
Expected publication date:
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-January 2024 when we will write to stakeholders about how they can get involved. The deadline for submissions is expected in approximately mid-March 2024.